Hepatitis B Challenge Dose in Adults (V232-059-10)

A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥50 Years Old) Vaccinated With a Primary Series of an Hepatitis B Vaccine

The purpose of this trial is to describe the Seroprotection Rate (SPR) at least 2 years following completion of a primary series with a hepatitis B vaccine (Base Study V232-059, NCT00440531) and 1 month following a challenge dose with a Modified Process Hepatitis B vaccine.

Inclusion Criteria:

• In general good health based on a medical history.
• Received 3 doses of an Hepatitis B vaccine in Base Study V232-059, NCT00440531 at least 2 years prior to enrollment in this study.

Exclusion Criteria:

• Known history of previous Hepatitis B infection.
• History of vaccination with any Hepatitis B vaccine within the last 2 years.
• History of febrile illness.
• Known or suspected hypersensitivity to any component of HBVaxPro.
• Receipt of medication / vaccine that may interfere with study assessments.
• Known or suspected immune impairment.
• Pregnant women and nursing mothers.